Enzo Biochem (ENZ) 10-Q 9 Jun 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Apr. 30, 2020	Jun. 01, 2020
Document Information Line Items
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		47,890,883
Amendment Flag	false
Entity Central Index Key	0000316253
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Document Period End Date	Apr. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-09974
Entity Incorporation, State or Country Code	NY
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 30, 2020	Jul. 31, 2019
ASSETS
Cash and cash equivalents	$ 54,407	$ 60,146
Accounts receivable, net	6,817	10,738
Inventories	8,018	7,842
Prepaid expenses and other	3,058	2,727
Total current assets	72,300	81,453
Property, plant and equipment, net	13,295	14,254
Right-of-use assets	20,812
Goodwill	7,452	7,452
Intangible assets, net	588	1,032
Other assets, including restricted cash of $750	1,901	2,449
Total assets	116,348	106,640
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable – trade	8,523	7,256
Accrued liabilities	11,714	8,362
Other current liabilities	7,151	391
Finance leases short term	225
Current portion of operating lease liabilities	4,257
Total current liabilities	31,870	16,009
Long term debt – net	4,509	4,179
Operating lease liabilities, non-current	17,416
Other liabilities and finance leases long term	223	424
Total liabilities	54,018	20,612
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 47,890,883 at April 30, 2020 and 47,556,807 at July 31, 2019	479	476
Additional paid-in capital	334,268	332,704
Accumulated deficit	(274,927)	(249,732)
Accumulated other comprehensive income	2,510	2,580
Total stockholders’ equity	62,330	86,028
Total liabilities and stockholders’ equity	$ 116,348	$ 106,640

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Apr. 30, 2020	Jul. 31, 2019
Statement of Financial Position [Abstract]
Other assets, including restricted cash (in Dollars)	$ 750	$ 750
Preferred stock par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	47,890,883	47,556,807
Common Stock, shares outstanding	47,890,883	47,556,807

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Income Statement [Abstract]
Revenues	$ 16,903	$ 19,662	$ 56,494	$ 60,249
Operating costs and expenses:
Cost of revenues	12,478	14,360	40,574	43,347
Research and development	1,163	781	3,282	2,342
Selling, general and administrative	11,061	10,920	32,893	33,387
Legal and related expense	1,925	257	5,681	2,700
Legal settlements, net.		(28,925)		(28,925)
Total operating costs, expenses and legal settlements, net	26,627	(2,607)	82,430	52,851
Operating (loss) income	(9,724)	22,269	(25,936)	7,398
Other income (expense):
Interest, net	87	258	495	759
Other	135	70	334	249
Foreign exchange loss	(358)	(332)	(88)	(530)
(Loss) income before income taxes	(9,860)	22,265	(25,195)	7,876
Net (loss) income	$ (9,860)	$ 22,265	$ (25,195)	$ 7,876
Net loss (income) per common share:
Basic (in Dollars per share)	$ (0.21)	$ 0.47	$ (0.53)	$ 0.17
Diluted (in Dollars per share)	$ (0.21)	$ 0.47	$ (0.53)	$ 0.17
Weighted average common shares outstanding:
Basic (in Shares)	47,780	47,452	47,668	47,259
Diluted (in Shares)	47,780	47,555	47,668	47,364

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (9,860)	$ 22,265	$ (25,195)	$ 7,876
Other comprehensive gain (loss):
Foreign currency translation adjustments	284	206	(70)	278
Comprehensive (loss) income	$ (9,576)	$ 22,471	$ (25,265)	$ 8,154

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balance at Jul. 31, 2018	$ 472	$ 330,770	$ (252,221)	$ 2,100	$ 81,121
Balance (in Shares) at Jul. 31, 2018	47,182,254
Net income (loss)			7,876		7,876
Exercise of stock options	$ 1	166			167
Exercise of stock options (in Shares)	34,719
Issuance of common stock for options exercised by Directors (in Shares)	23,376
Share-based compensation charges		725			725
Vesting of restricted stock (in Shares)	986
Issuance of common stock for employee 401(k) plan match	$ 3	829			832
Issuance of common stock for employee 401(k) plan match (in Shares)	315,472
Foreign currency translation adjustments				278	278
Balance at Apr. 30, 2019	$ 476	332,490	(244,345)	2,378	90,999
Balance (in Shares) at Apr. 30, 2019	47,556,807
Balance at Jan. 31, 2019	$ 472	331,463	(266,610)	2,172	67,497
Balance (in Shares) at Jan. 31, 2019	47,241,335
Net income (loss)			22,265		22,265
Exercise of stock options	$ 1	72			73
Issuance of common stock for options exercised by Directors		(73)			(73)
Share-based compensation charges		199			199
Issuance of common stock for employee 401(k) plan match	$ 3	829			832
Issuance of common stock for employee 401(k) plan match (in Shares)	315,472
Foreign currency translation adjustments				206	206
Balance at Apr. 30, 2019	$ 476	332,490	(244,345)	2,378	90,999
Balance (in Shares) at Apr. 30, 2019	47,556,807
Balance at Jul. 31, 2019	$ 476	332,704	(249,732)	2,580	86,028
Balance (in Shares) at Jul. 31, 2019	47,556,807
Net income (loss)			(25,195)		(25,195)
Share-based compensation charges		728			728
Vesting of restricted stock (in Shares)	811
Issuance of common stock for employee 401(k) plan match	$ 3	836			839
Issuance of common stock for employee 401(k) plan match (in Shares)	333,265
Foreign currency translation adjustments				(70)	(70)
Balance at Apr. 30, 2020	$ 479	334,268	(274,927)	2,510	62,330
Balance (in Shares) at Apr. 30, 2020	47,890,883
Balance at Jan. 31, 2020	$ 476	333,225	(265,067)	2,226	70,860
Balance (in Shares) at Jan. 31, 2020	47,557,618
Net income (loss)			(9,860)		(9,860)
Share-based compensation charges		209			209
Issuance of common stock for employee 401(k) plan match	$ 3	834			837
Issuance of common stock for employee 401(k) plan match (in Shares)	333,265
Foreign currency translation adjustments				284	284
Balance at Apr. 30, 2020	$ 479	$ 334,268	$ (274,927)	$ 2,510	$ 62,330
Balance (in Shares) at Apr. 30, 2020	47,890,883

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Cash flows from operating activities:
Net (loss) income	$ (25,195)	$ 7,876
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment	1,700	1,631
Amortization of intangible assets	451	741
Share-based compensation charges	728	725
Accrual for share-based 401(k) employer match expense	631	461
Foreign exchange loss	8	650
Changes in operating assets and liabilities:
Accounts receivable	3,942	1,605
Inventories	(147)	(456)
Prepaid expenses and other assets	223	(36)
Accounts payable – trade	1,211	(3,363)
Accrued liabilities, other current liabilities and other liabilities	4,330	(1,853)
Total adjustments	13,077	105
Net cash (used in) provided by operating activities	(12,118)	7,981
Cash flows from investing activities:
Capital expenditures	(719)	(7,554)
Net cash used in investing activities	(719)	(7,554)
Cash flows from financing activities:
Proceeds from borrowing under government programs and mortgage agreement	7,412	4,500
Repayments under mortgage agreement and finance leases	(321)	(244)
Cost to obtain loan		(72)
Proceeds from exercise of stock options		166
Net cash provided by financing activities	7,091	4,350
Effect of exchange rate changes on cash and cash equivalents	7	(16)
(Decrease) increase in cash and cash equivalents and restricted cash	(5,739)	4,761
Cash and cash equivalents and restricted cash - beginning of period	60,896	60,041
Total cash and cash equivalents and restricted cash - end of period	55,157	64,802
The composition of total cash and cash equivalents and restricted cash is as follows:
Cash and cash equivalents	54,407	64,052
Restricted cash included in other assets	750	750
Total cash and cash equivalents and restricted cash	$ 55,157	$ 64,802

Basis of Presentation

Basis of Presentation	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics, Enzo Realty LLC and Enzo Realty II LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of April 30, 2020, the consolidated statements of operations, comprehensive income (loss) and stockholders’ equity for the three and nine months ended April 30, 2020 and 2019, and the consolidated statements of cash flows for the nine months ended April 30, 2020 and 2019 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2019 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2019 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2020. A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. Through the six month period ended January 31, 2020, we had experienced growth in our laboratory testing services accessions and our products volume compared to the prior year period. This growth continued into February 2020. However, beginning in March 2020, the Company experienced a material decline in its laboratory testing volumes due to the COVID-19 pandemic as patients have reduced physician office visits. Additionally, customers of our products have reduced or suspended purchases because they have temporarily reduced or closed their operations on a global basis. The COVID-19 impact on the Company’s operations is consistent with the overall industry and publicly issued statements from competitors, partners, and vendors. The decline in our laboratory accessions and customer orders for products continued during most of the remainder of the third fiscal quarter (ended April 30, 2020) and only began to show some improvement in the month of April. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, the aforementioned significant reduction in physician office visits, the cancellation of elective medical procedures, customers of our products closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies. The Company believes the COVID-19 pandemic may continue to have a negative impact on the Company’s operating results, cash flows and financial condition for an undetermined amount of time. Global supply chain issues due to the pandemic may hamper both production of products within the life science division as well as testing capabilities in the clinical laboratory. It is possible that the Company may experience an adverse impact on cash collections from customers, clients and payers as a result of the impact of the COVID-19 pandemic. The extent to which our businesses may be affected by the COVID-19 pandemic will largely depend on both current and future developments, including its duration, spread and treatment, and related work and travel advisories and restrictions, all of which are highly uncertain and cannot be reasonably predicted at this time. The Company expects its COVID-19 related products and services to partially offset revenue declines. Enzo has publicly announced that it has applied its technical expertise in molecular diagnostics and serological testing to develop next generation COVID-19 and related antibody testing options. Enzo’s innovations include virus-inactivating specimen collection media to lessen transmission risks for healthcare providers and clinical laboratory personnel, the development of more relevant positive controls for the tests, and improved sensitivity. However, it is too early to determine the significance of any positive impact from increased testing and the Company’s proprietary product offerings on revenue, profitability and cash flow. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was passed in March 2020 and addresses the various economic impacts of, and otherwise responds to, the COVID-19 (coronavirus) outbreak. Under the CARES Act, we received a loan, an advance payment, and an income grant during the period ended April 30, 2020 which are further described in this report. Use of Estimates The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of April 30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s implicit price concessions and credit losses, accounts receivable and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. Effect of New Accounting Pronouncements Adoption of New Accounting Standards On August 1, 2019, the Company adopted a new accounting standard issued by the Financial Accounting Standards Board (“FASB”) on accounting for leases using the modified retrospective method. This new accounting standard requires a lessee to recognize an asset and liability for most leases on its balance sheet. The Company elected the optional transition method that allowed for a cumulative-effect adjustment to the opening balance of retained earnings recorded on August 1, 2019 and did not restate previously reported results in the comparative periods. The Company also elected the package of practical expedients, which among other things, allowed it to carry forward its historical lease classification. As a result of adoption of the new standard, the Company recorded right-of-use assets and lease liabilities of approximately $24.4 million and $25.1 million, respectively as of August 1, 2019. The operating lease liability was determined based on the present value of the remaining minimum rental payments and the right-of-use asset was determined based on the value of the lease liability, adjusted for deferred rent balances of approximately $0.7 million, which were previously included in accrued expenses. There was no cumulative effect adjustment to the opening balance of accumulated deficit. Accounting for the Company’s finance leases remains substantially unchanged. The adoption of the new standard did not materially impact the Company’s consolidated results of operations or cash flows. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. The Company elected the package of three practical expedients. As such, the Company did not reassess whether expired or existing contracts are or contain a lease and did not need to reassess the lease classifications or reassess the initial direct costs associated with expired or existing leases. The Company did not elect the hindsight practical expedient. Further, the land easement practical expedient was not elected as the practical expedient is not applicable to the Company. The Company elected to take the practical expedient to not separate lease and non-lease components of all asset classes entered into or modified after the effective date. For further details, see Note 8. Pronouncements Issued but Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326). This standard changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a new forward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoption of this standard is required for our annual and interim periods beginning August 1, 2023, the effective date for smaller reporting companies and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial position and cash flows. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations. Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 22% of Clinical Services net revenue for the three month period and 26% for the nine month period ended April 30, 2020 and 42% of Clinical Services net revenue for each of the three and nine month periods ended April 30, 2019. As of April 30, 2020, other than the Medicare program, one provider whose programs are included in either “Third-party payers” and/or “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 12% of Clinical Services net receivables. Income Taxes The benefit for income taxes and the effective tax rates for the three and nine months ended April 30, 2020 and 2019 is $0 and 0%, respectively. The primary difference between the Company’s effective tax rates and the statutory rates for the three and nine months ended April 30, 2020 and 2019 is due to the change in net operating losses for which a full valuation allowance is maintained. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize its deferred tax assets.

Net income (loss) per share

Net income (loss) per share	9 Months Ended
	Apr. 30, 2020
Earnings Per Share [Abstract]
Net income (loss) per share	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three months ended April 30, 2020 and nine months ended April 30, 2020 diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three and nine months ended April 30, 2020, approximately 40,000 and 56,000, respectively of potential common shares (“in the money options”) and unvested restricted stock were excluded from the calculation of diluted earnings per share. For the three and nine months ended April 30, 2020, the effect of approximately 2,201,000 and 1,805,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted earnings per share because their effect would be antidilutive. For the three and nine months ended April 30, 2019, the effect of approximately 1,640,000 and 1,541,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Apr. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 – Revenue Recognition Clinical Services Revenue Net services revenues in the Company’s clinical services business accounted for 58% and 63% of the Company’s total net revenues for the nine months ended April 30, 2020 and 2019, respectively and are primarily comprised of a high volume of relatively low-dollar transactions. The services business, which provides clinical testing services, satisfies its performance obligation and recognizes revenues upon completion of the testing process for a specific patient and reporting to the ordering physician. The Company may also perform clinical testing services for other laboratories and will recognize revenue from those services when reported to the ordering laboratory. The Company estimates the amount of consideration it expects to receive from customer groups using the portfolio approach. These estimates of the expected consideration include the impact of contractual allowances and price concessions on our customer group portfolios consisting of healthcare insurers, government payers, client payers and patients as described below. Contracts with customers in our laboratory services business do not contain a financing component, based on the typically limited period of time between performance of services and collection of consideration. The transaction price includes variable consideration in the form of the contractual allowance and price concessions as well as the collectability of the transaction based on the patient intent and ability to pay. The Company uses the expected value method in estimating the amount of the variability included in the transaction price. The following are descriptions of our laboratory services business portfolios: Third party payers and Health Maintenance Organizations (HMO’s) Reimbursements from third party payers, primarily healthcare insurers, and HMO’s are based on negotiated fee-for-service schedules. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical collection and denial experience and the terms of the Company’s contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded upon settlement. Collection of the consideration the Company expects to receive is normally a function of providing complete and correct billing information to these third party payers within the various filing deadlines, and typically occurs within 60 to 90 days of billing. Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, will reserve accordingly for the billing. Third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payers in interpretations, requirements, and “conditions of participation” in various programs. Government Payer - Medicare Reimbursements from Medicare are based on fee-for-service schedules set by Medicare, which is funded by the government. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from Medicare, which considers historical collection and denial experience and other factors. Adjustments to the allowances, based on actual receipts from the government payers, are recorded upon settlement. Collection of consideration the Company expects to receive is normally a function of providing the complete and correct billing information within the various filing deadlines and typically occurs within 60 days of billing. Provided the Company has billed the government payer accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve accordingly for the billing. Patient self-pay Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Coinsurance and deductible responsibilities based on fees negotiated with healthcare insurers are also billed to insured patients and included in this portfolio. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company’s policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Patient responsibility is invoiced and if it reaches 91 days outstanding, the account is sent to a collection agency for further processing. After the account has been with the collection agency for at least 105 days, and is determined to be uncollectable it is written off. The following table represents clinical services net revenues and percentages by type of customer: Three months ended Three months ended Revenue category Third-party payer $ 5,082 52 % $ 5,799 50 % Medicare 1,870 19 2,634 22 Patient self-pay 1,655 17 1,881 16 HMO’s 1,132 12 1,437 12 Total $ 9,739 100 % $ 12,000 100 % Nine months ended Nine months ended Revenue category Third-party payer $ 17,878 51 % $ 20,213 53 % Medicare 8,048 23 7,724 20 Patient self-pay 4,621 13 5,652 15 HMO’s 4,485 13 4,459 12 Total $ 35,032 100 % $ 38,048 100 % For the nine months ended April 30, 2020 and 2019, all of the Company’s clinical services were provided within the United States. Grant income Under the CARES Act, we were eligible for and received a $747 income grant under the Department of Health and Human Services (HHS) Public Health and Social Services Emergency Fund for provider relief. The purpose of the payment is to reimburse the Company for health care related expenses or lost revenues attributable to COVID-19. We have certified that the grant funds were accepted per the regulations and have recognized it as Grant income for the three and nine month periods ended April 30, 2020 in the Clinical Services segment. In April 2020, the HHS began an additional general distribution to Medicare facilities and providers impacted by COVID-19, augmenting the first amount that was established in March. In May 2020, we applied for a second grant from the Emergency Fund, which has not yet been received. Products Revenue Products revenue consists of the sale of single-use products used in the identification of genomic information and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. Products revenue by geography is as follows: Three Months Ended April 30 Nine Months Ended April 30 2020 2019 2020 2019 United States $ 3,458 $ 4,585 $ 11,652 $ 12,571 Europe 1,793 2,297 5,740 6,347 Rest of the world 1,166 1,029 3,323 3,283 Products revenue $ 6,417 $ 7,911 $ 20,715 $ 22,201

Supplemental disclosure for sta

Supplemental disclosure for statement of cash flows	9 Months Ended
	Apr. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Supplemental disclosure for statement of cash flows	Note 4 - Supplemental disclosure for statement of cash flows For the nine months ended April 30, 2020 and 2019, interest paid by the Company was $204 and $138, respectively. For the nine months ended April 30, 2020, reductions in the measurement of right of use assets and liabilities included in cash flows from operating activities was approximately $4,300 for each, with the net amount of such changes included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cash flows. For the nine months ended April 30, 2020 and 2019, tax on capital paid by the Company was $79 and $94, respectively. During the nine months ended April 30, 2020 and 2019, the Company issued common stock in connection with its share based 401(k) employer match in the amount of $836 and $832, respectively. For the nine months ended April 30, 2020, non-cash activities related to the adoption of the new accounting standard for leases are detailed in Note 1.

Inventories

Inventories	9 Months Ended
	Apr. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Note 5 – Inventories Inventories consist of the following: April 30, July 31, Raw materials $ 907 $ 876 Work in process 2,652 2,566 Finished products 4,459 4,400 $ 8,018 $ 7,842

Goodwill and intangible assets

Goodwill and intangible assets	9 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Note 6 – Goodwill and intangible assets At April 30, 2020 and July 31, 2019, the Company has goodwill of $7,452 allocated to the Clinical Services reporting unit. The Company’s change in the carrying amount of intangible assets, all in the Products segment is as follows: Gross Accumulated Amortization Net July 31, 2019 $ 27,238 $ (26,206 ) $ 1,032 Amortization expense — (451 ) (451 ) Foreign currency translation 47 (40 ) 7 April 30, 2020 $ 27,285 $ (26,697 ) $ 588 Intangible assets, all finite lived, consist of the following: April 30, 2020 July 31, 2019 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (11,010 ) $ 17 $ 11,027 $ (10,996 ) $ 31 Customer relationships 11,791 (11,220 ) 571 11,746 (10,745 ) 1,001 Website and acquired content 1,009 (1,009 ) — 1,008 (1,008 ) — Licensed technology and other 475 (475 ) — 483 (483 ) — Trademarks 2,983 (2,983 ) — 2,974 (2,974 ) — Total $ 27,285 $ (26,697 ) $ 588 $ 27,238 $ (26,206 ) $ 1,032 At April 30, 2020, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average Customer relationships 8 -15 years Less than 1 year Other intangibles 10 years Less than 2 years At April 30, 2020, the weighted average remaining useful life of intangible assets is approximately one year.

Loans Payable

Loans Payable	9 Months Ended
	Apr. 30, 2020
Debt Disclosure [Abstract]
Loans Payable	Note 7 - Loans Payable In connection with the purchase of our new facility, on November 27, 2018, a wholly-owned subsidiary (the ““mortgagor subsidiary”) of the Company entered into a Fee Mortgage and Security Agreement (the “mortgage agreement”) with Citibank, N.A. (the “mortgagee”). The mortgage agreement provides for a loan of $4.5 million for a term of 10 years, bears a fixed interest rate of 5.09% per annum and requires monthly mortgage payments of principal and interest of $30. Debt issuance costs of $72 are being amortized over the life of the mortgage agreement. The balance of unamortized debt issuance cost was $62 at April 30, 2020. At April 30, 2020, the balance owed by the subsidiary under the mortgage agreement was $4.3 million. The Company’s obligations under the mortgage agreement are secured by the new facility and by a $750 cash collateral deposit with the mortgagee as additional security. This restricted cash is included in other assets as of April 30, 2020. The mortgage agreement includes affirmative and negative covenants and events of default, as defined. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material changes in business, breach of representations, bankruptcy or insolvency, and changes in control. The mortgage includes certain financial covenants. As of April 30, 2020, required financial covenants have been met. We assumed from the seller an operating lease for a current tenant at the facility which was extended to June 30, 2020. Rental income from the assumed lease is included in other income. Minimum future annual principal payments under the mortgage agreement as of April 30, 2020, are as follows: July 31, 2020 $ 35 2021 144 2022 152 2023 160 2024 167 Thereafter 3,653 $ 4,311 Less: Current portion (142 ) Unamortized mortgage cost (62 ) $ 4,107 In April 2020, our subsidiary in Switzerland received a loan of CHF 0.4 million ($ 0.4 million, based on the foreign exchange rate as of April 30, 2020) from the Swiss government under the “Corona Krise” emergency loan program in response to the pandemic. This loan is uncollateralized, bears 0% interest, is due in 5 years, and may be repaid at any time. This loan is included in long term debt – net as of April 30, 2020. The CARES Act expanded the U.S. Small Business Administration’s (SBA) business loan program to create the Paycheck Protection Program (PPP), which provides employers with uncollateralized loans whose primary purpose is to retain or maintain workforce and salaries for a twenty four week period (“covered period”) following receipt of the loan. Currently, PPP loans have a 1% fixed interest rate and are due from two to five years. The primary features of the PPP loan program are to provide funding to companies to cover eligible expenses, and the potential for forgiveness of that portion of the loan spent on payroll and other permitted operating expenses during the covered period, subject to reductions if the borrower fails to maintain or restore employee and salary levels. We applied for a PPP loan based on the eligibility and need requirements established when the program was announced and in April 2020, the Company received $7,000 through Citibank N.A., the Company’s existing lender, pursuant to the PPP (the “PPP Loan”). The PPP Loan matures on April 17, 2022 (the “Maturity Date”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty. No interest payments are due within the initial six months of the PPP Loan. The interest accrued during the initial six-month period is due and payable, together with the principal, on the Maturity Date. The Company intends to use all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments to support business continuity throughout the COVID-19 pandemic. All or a portion of the PPP Loan may be forgiven by the SBA upon application by the Company and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty four week period beginning on the date of receipt of the PPP loan with certain stipulated restrictions. Due to uncertainties with respect to loan forgiveness calculations and government pronouncements with respect to eligibility, we did not recognize any loan forgiveness as of April 30, 2020 and have classified the loan in other current liabilities as we expect to earn loan forgiveness by the end of the covered period. The SBA has announced its intention to audit loans in excess of $2.0 million. No assurance can be given that we will obtain forgiveness of the PPP loan in whole or in part.

Leases

Leases	9 Months Ended
	Apr. 30, 2020
Leases Disclosure [Abstract]
Leases	Note 8 - Leases During the first quarter of fiscal 2020, the Company adopted ASU No. 2016-02 “Leases (Topic 842)”, which requires leases with durations greater than twelve months to be recognized on the balance sheet. The Company adopted the standard using the modified retrospective approach with an effective date of August 1, 2019. The Company did not apply the new standard to comparative periods and therefore those amounts are not presented below. The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, patient service centers, and equipment primarily through operating leases, and equipment through a limited number of finance leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company’s leases generally do not provide an implicit rate. The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e. payments related to maintenance fees, utilities, etc.,) which have generally been combined and accounted for as a single lease component. The Company’s leases have remaining terms of less than 1 year to 9 years, some of which include options to extend the leases for up to 5 years. The Company’s lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain of the Company’s lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities. Leases Balance Sheet Classification April 30, 2020 Assets Operating Right-of-use assets $ 20,812 Finance Property, plant and equipment, net (a) 459 Total lease assets $ 21,271 Liabilities Current: Operating Current portion of operating lease liabilities $ 4,257 Finance Finance leases short term 225 Non-current: Operating Operating lease liabilities, non-current 17,416 Finance Other liabilities and finance leases long term 223 Total lease liabilities $ 22,121 (a) Accumulated amortization of finance lease assets was approximately $0.9 million as of April 30, 2020. Components of lease cost for the three and nine months ended April 30, 2020 were as follows: Lease cost Three Months Ended April 30, 2020 Nine Ended April 30, 2020 Operating lease cost $ 1,466 $ 4,414 Finance lease cost: Amortization of leased assets 61 177 Interest on lease liabilities 7 29 Total lease cost $ 1,534 $ 4,620 The maturity of the Company’s lease liabilities as of April 30, 2020 is as follows: Maturity of lease liabilities Operating leases Finance leases Total Remainder of fiscal 2020 $ 1,473 $ 84 $ 1,557 2021 4,997 188 5,185 2022 3,786 88 3,874 2023 3,284 88 3,372 2024 3,273 37 3,310 Thereafter 9,606 — 9,606 Total lease payments 26,419 485 26,904 Less: Interest (a) (4,746 ) (37 ) (4,783 ) Present value of lease liabilities $ 21,673 $ 448 $ 22,121 (a) Primarily calculated using the Company’s incremental borrowing rate. Lease term and discount rate for the nine months ended April 30, 2020 were as follows: Lease term and discount rate Weighted-average remaining lease term (years): Operating leases 6.4 years Finance leases 2.7 years Weighted-average discount rate: Operating leases 4.9 % Finance leases 8.1 % See Note 4 for cash flow information on cash paid for amounts included in the measurement of lease liabilities for the nine months ended April 30, 2020.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Apr. 30, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	Note 9 – Accrued Liabilities Accrued liabilities consist of the following: April 30, July 31, Payroll, benefits, and commissions $ 4,866 $ 5,123 Professional fees 806 774 Legal 2,333 164 Deferred revenue – CARES Act Advance Payment 2,526 — Other 1,183 2,301 $ 11,714 $ 8,362 In order to increase cash flow to providers of services and suppliers impacted by the pandemic, the Centers for Medicare and Medicaid Services (CMS) expanded its Accelerated and Advance Payment Program to a broader group of Medicare providers. We applied for and received a $2,526 payment advance from this program in April 2020. The recoupment by CMS of our advance payment begins 120 days after the date of receipt, at which time every claim we submit from that point will be automatically offset to repay the advance payment. Any unrecouped advance balance remaining after 90 days of the recoupment process must then be repaid such that 210 days after receiving the advance it will be entirely repaid.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Apr. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 10 – Stockholders’ Equity Controlled Equity Offering The Company has a Controlled Equity Offering SM On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017. During the nine months ended April 30, 2020 and 2019, the Company did not sell any shares of Common Stock under the Sales Agreement. Share-based compensation In January 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) which provides for the issuance of equity awards, including among others, options, restricted stock and restricted stock units for up to 3,000,000 Common Shares. The exercise price of options granted under the 2011 Plan, and consistent with other Plans, is equal to or greater than fair market value of the Common Stock on the date of grant. Unless terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such time as no shares of Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date of the 2011 Plan. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan to increase the number of shares available for issuance by 2,000,000 bringing the total number of shares available for award under the 2011 Plan to 5,000,000. Awards outstanding upon expiration of the 2011 Plan shall remain in effect until they have been exercised, terminated, or have expired. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 935,000 shares as of April 30, 2020. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2020 2019 2020 2019 Stock options $ 206 $ 289 $ 724 $ 521 Restricted stock 1 2 4 5 $ 207 $ 291 $ 728 $ 526 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2020 2019 2020 2019 Selling, general and administrative $ 207 $ 291 $ 728 $ 526 $ 207 $ 291 $ 728 $ 526 No excess tax benefits were recognized during the nine month periods ended April 30, 2020 and 2019. Stock Option Plans The following table summarizes stock option activity during the nine month period ended April 30, 2020: Options Weighted Weighted Aggregate Outstanding at July 31, 2019 2,351,040 $ 4.53 Awarded 773,032 $ 2.40 Exercised — — $ — Cancelled or expired (485,076 ) $ 3.71 Outstanding at end of period 2,638,996 $ 4.05 3.2 years $ 637 Exercisable at end of period 1,457,162 $ 5.10 1.7 years $ 78 As of April 30, 2020, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $1.2 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately fifteen months. The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options. Performance Stock Units To better align the long-term interest of executives with growing U.S. practices, beginning in fiscal 2018, the Company granted long-term incentive awards in the form of time based stock options and performance-based restricted stock units (“Performance Stock Units” or “PSUs”). The PSUs earned will be determined over a three-year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth. Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performance relative to Enzo’s peer group. During the nine months ended April 30, 2020 and fiscal years ended 2019 and 2018, the Company awarded PSUs to its executive officers, this award provides for the grant of shares of our common stock at the end of a three–year period based on the achievement of average revenue growth and adjusted EBITDA growth over that period. During the nine months ended April 30, 2020, one former executive forfeited a total of 14,500 PSUs. As of April 30, 2020, the Company did not accrue any compensation expense for these PSU’s as the achievement of the growth goals is currently not probable. The following table summarizes PSU’s granted and outstanding as of April 30, 2020: Grant Date Total Grant Forfeitures Outstanding Fair Market Value At Grant Date (000s) 7/31/2018 32,000 (4,000 ) 28,000 $ 124 1/3/2019 80,500 (10,500 ) 70,000 $ 196 2/25/2020 98,600 — 98,600 $ 217 Restricted Stock Awards The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2020, there were 817 shares of unvested restricted stock which have a weighted average award price of $3.34 per share. As of April 30, 2020, there was approximately $4 of unrecognized compensation cost related to these unvested shares of restricted stock to be recognized over a weighted average remaining period of approximately nine months. There were no awards made during the nine months ended April 30, 2020. During the nine months ended April 30, 2020, a total of 811 restricted stock awards vested whose fair value was approximately $2.

Segment reporting

Segment reporting	9 Months Ended
	Apr. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	Note 11 – Segment reporting The Company has three reportable segments: Products, Clinical Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal and related expense specific to other segments’ activities have been allocated to those segments. Legal settlements, net, represent activities for which royalties would have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2020 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 9,739 $ 6,417 — — $ 16,156 Grant income 747 — — — 747 Total 10,486 6,417 — — 16,903 Operating costs and expenses: Cost of revenues 9,133 3,345 — — 12,478 Research and development 395 580 $ 188 — 1,163 Selling, general and administrative 5,902 2,667 — $ 2,492 11,061 Legal and related expenses 52 — — 1,873 1,925 Total operating costs and expenses 15,482 6,592 188 4,365 26,627 Operating loss (4,996 ) (175 ) (188 ) (4,365 ) (9,724 ) Other income (expense): Interest (7 ) 11 — 83 87 Other 1 4 — 130 135 Foreign exchange loss — (358 ) — — (358 ) Loss before income taxes $ (5,002 ) $ (518 ) $ (188 ) $ (4,152 ) $ (9,860 ) Depreciation and amortization included above $ 373 $ 278 $ — $ 66 $ 717 Share-based compensation included in above: Selling, general and administrative 21 14 — 172 207 Total $ 21 $ 14 $ — $ 172 $ 207 Capital expenditures $ 225 $ 60 $ — $ — $ 285 Three months ended April 30, 2019 Clinical Products Therapeutics Other Consolidated Revenues $ 11,751 $ 7,911 — — $ 19,662 Operating costs, expenses and legal settlements, net: Cost of revenues 10,963 3,397 — — 14,360 Research and development 31 527 $ 223 — 781 Selling, general and administrative 5,960 2,923 — $ 2,037 10,920 Legal fee expense 35 16 — 206 257 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses, and legal settlements, net 16,989 (22,062 ) 223 2,243 (2,607 ) Operating income (loss) (5,238 ) 29,973 (223 ) (2,243 ) 22,269 Other income (expense): Interest (18 ) 19 — 257 258 Other 6 — — 64 70 Foreign exchange loss — (332 ) — — (332 ) (Loss) income before income taxes $ (5,250 ) $ 29,660 $ (223 ) $ (1,922 ) $ 22,265 Depreciation and amortization included above $ 440 $ 340 $ — $ 58 $ 838 Share-based compensation included in above: Selling, general and administrative 40 24 — 135 199 Total $ 40 $ 24 $ — $ 135 $ 199 Capital expenditures $ 120 $ 446 $ — $ — $ 566 Nine months ended April 30, 2020 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 35,032 $ 20,715 — — $ 55,747 Grant income 747 — — — 747 Total 35,779 20,715 — — 56,494 Operating costs and expenses: Cost of revenues 30,351 10,223 — — 40,574 Research and development 1,118 1,599 $ 565 — 3,282 Selling, general and administrative 18,012 7,954 — $ 6,927 32,893 Legal and related expenses 140 1 — 5,540 5,681 Total operating costs and expenses 49,621 19,777 565 12,467 82,430 Operating income (loss) (13,842 ) 938 (565 ) (12,467 ) (25,936 ) Other income (expense): Interest (29 ) 45 — 479 495 Other 20 (1 ) — 315 334 Foreign exchange loss — (88 ) — — (88 ) Income (loss) before income taxes $ (13,851 ) $ 894 $ (565 ) $ (11,673 ) $ (25,195 ) Depreciation and amortization included above $ 1,174 $ 781 $ — $ 196 $ 2,151 Share-based compensation included in above: Selling, general and administrative 88 58 — 582 728 Total $ 88 $ 58 $ — $ 582 $ 728 Capital expenditures $ 514 $ 205 $ — $ — $ 719 Nine months ended April 30, 2019 Clinical Products Therapeutics Other Consolidated Revenues $ 38,048 $ 22,201 — — $ 60,249 Operating costs, expenses and legal settlements, net: Cost of revenues 32,956 10,391 — — 43,347 Research and development 31 1,645 $ 668 — 2,344 Selling, general and administrative 18,220 8,828 — $ 6,339 33,387 Legal fee expense 109 24 — 2,567 2,700 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses and legal settlements, net 51,316 (8,037 ) 668 8,906 52,853 Operating income (loss) (13,268 ) 30,238 (668 ) (8,906 ) 7,396 Other income (expense): Interest (51 ) 49 — 761 759 Other 17 — — 232 249 Foreign exchange loss (gain) — (530 ) — — (530 ) (Loss) income before income taxes $ (13,302 ) $ 29,757 $ (668 ) $ (7,913 ) $ 7,874 Depreciation and amortization included above. $ 1,217 $ 1,025 $ — $ 130 $ 2,372 Share-based compensation included in above: Selling, general and administrative 118 74 — 553 725 Total $ 118 $ 74 $ — $ 553 $ 725 Capital expenditures $ 883 $ 524 $ — $ 6,147 $ 7,554

Contingencies

Contingencies	9 Months Ended
	Apr. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 12 – Contingencies The Company has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017, the Court ruled that the asserted claims of the ‘180 and ‘405 Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That ruling was affirmed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) in June 2019. Enzo subsequently filed a petition for certiorari regarding the invalidity ruling for the ‘180 and ‘405 Patents in February 2020; the Supreme Court denied Enzo’s petition on March 30, 2020. There are currently two cases that were originally brought by the Company in the Court. In those two cases, Enzo alleges patent infringement against Becton Dickinson Defendants and Roche Defendants, respectively. The claims in those cases involve the ‘197 Patent. Both cases are stayed. In separate inter partes review proceedings before the U.S. Patent and Trademark Office involving, among others, Becton Dickinson, certain claims of the ‘197 Patent were found unpatentable as anticipated or obvious and cancelled by the Patent Trial and Appeals Board (“Board”). Enzo appealed that decision to the Federal Circuit. On August 16, 2019, the Federal Circuit affirmed the Board’s decision, finding that each of the challenged claims is unpatentable. The Company filed a petition for rehearing and rehearing en banc on October 30, 2019, which the Federal Circuit denied on December 4, 2019. The Company filed a petition for certiorari with the Supreme Court on March 3, 2020, which is pending. In April 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court. As a result, Enzo dismissed (1) a stayed patent litigation regarding the ’180 and ’197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’s appeal in the litigation involving the ’581 Patent that involved both Hologic and Grifols. As a result of the agreement with Hologic, Hologic withdrew from Enzo’s Federal Circuit appeal of the Board’s adverse rulings in the inter partes On February 5, 2020, plaintiffs Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (“Plaintiffs”) filed a complaint in the United States District Court for the Southern District of New York in connection with the Company’s 2020 annual meeting (the “Annual Meeting”). The Complaint names the Company, Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky and Rebecca Fischer as defendants (“Defendants”). On March 26, 2020, Plaintiffs filed an amended verified complaint against the Defendants. Plaintiffs assert claims (i) against the Company for alleged violation of Section 14(a) of the Securities and Exchange Act (the "Exchange Act") and Rule 14a-9 thereunder in connection with two public statements by the Company concerning the Annual Meeting; (ii) against the individual defendants for alleged violation of Section 20 of the Exchange Act based on the Company's purported violation of Section 14(a) and Rule 14a-9; (iii) against the individual defendants for breach of fiduciary duty in connection with the Annual Meeting; and (iv) derivatively on behalf of the Company against the individual defendants for a declaration that any amendment of Article II, Section 2 of the Company's By-Laws requires the approval of the holders of at least 80% of the voting power of the then outstanding shares of the Company's stock entitled to vote generally in the election of directors, voting together as a single class, and a majority of such shares owned by persons not affiliated with an interested shareholder. Defendants' response to the amended complaint is now due on June 30, 2020. Discovery has not commenced. There can be no assurance that the Company will be successful in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations. As described in Note 3, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-party payer informed us outside of their typical business practice that they believe it overpaid the Company during certain periods of fiscal 2018. The Company disputed these claims and formally sent legal appeal letters to the payer. During the nine month 2020 period, we recorded $0.8 million in legal and related expenses as a result of reduced reimbursements this payer made to us. In April 2020, we and the payer entered into a settlement agreement and release whereby the parties agreed that the $0.8 million previously withheld by the payer shall fully and completely satisfy the dispute. The following legal settlements are included in the statement of operations under Legal settlements, net within the Life Science segment for the 2019 periods: The Company, along with its subsidiaries Enzo Life Sciences, Inc. entered into a Settlement Agreement as of February 5, 2019 (the “Agreement) with Roche Diagnostics GmbH and Roche Molecular Systems, Inc. (together, “Roche”) with respect to an action between the Company and Roche before the U.S. District Court, Southern District of New York, Case No 04-CV4046. Roche agreed to pay the Company $21 million in settlement pursuant to the Agreement. The Company received $19.4 million net of attorney contingency payments. This settlement does not affect the Company’s civil action for patent infringement against Roche in the U.S. District Court for the State of Delaware, Enzo Life Sciences Inc. v. Roche Molecular Systems Inc., et al., civil action No. 12 cv-00106, which remains pending on appeal. The Company, along with its subsidiaries Enzo Life Sciences, Inc. entered into a settlement and license agreement as of April 16, 2019 (the “Agreement”) with Hologic, Inc. (“Hologic”), Grifols, S.A., and Grifols Diagnostic Solutions Inc. (together, “Grifols”) to settle all outstanding patent disputes among the parties. The terms of the agreement include one-time payments totaling $14 million to the Company in exchange for fully paid-up, worldwide licenses to Hologic and Grifols. The Company received $9.5 million net of attorney contingency payments.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of April 30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s implicit price concessions and credit losses, accounts receivable and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.
Effect of New Accounting Pronouncements	Effect of New Accounting Pronouncements Adoption of New Accounting Standards On August 1, 2019, the Company adopted a new accounting standard issued by the Financial Accounting Standards Board (“FASB”) on accounting for leases using the modified retrospective method. This new accounting standard requires a lessee to recognize an asset and liability for most leases on its balance sheet. The Company elected the optional transition method that allowed for a cumulative-effect adjustment to the opening balance of retained earnings recorded on August 1, 2019 and did not restate previously reported results in the comparative periods. The Company also elected the package of practical expedients, which among other things, allowed it to carry forward its historical lease classification. As a result of adoption of the new standard, the Company recorded right-of-use assets and lease liabilities of approximately $24.4 million and $25.1 million, respectively as of August 1, 2019. The operating lease liability was determined based on the present value of the remaining minimum rental payments and the right-of-use asset was determined based on the value of the lease liability, adjusted for deferred rent balances of approximately $0.7 million, which were previously included in accrued expenses. There was no cumulative effect adjustment to the opening balance of accumulated deficit. Accounting for the Company’s finance leases remains substantially unchanged. The adoption of the new standard did not materially impact the Company’s consolidated results of operations or cash flows. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. The Company elected the package of three practical expedients. As such, the Company did not reassess whether expired or existing contracts are or contain a lease and did not need to reassess the lease classifications or reassess the initial direct costs associated with expired or existing leases. The Company did not elect the hindsight practical expedient. Further, the land easement practical expedient was not elected as the practical expedient is not applicable to the Company. The Company elected to take the practical expedient to not separate lease and non-lease components of all asset classes entered into or modified after the effective date. For further details, see Note 8. Pronouncements Issued but Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326). This standard changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a new forward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoption of this standard is required for our annual and interim periods beginning August 1, 2023, the effective date for smaller reporting companies and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial position and cash flows. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.
Concentration Risk	Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 22% of Clinical Services net revenue for the three month period and 26% for the nine month period ended April 30, 2020 and 42% of Clinical Services net revenue for each of the three and nine month periods ended April 30, 2019. As of April 30, 2020, other than the Medicare program, one provider whose programs are included in either “Third-party payers” and/or “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 12% of Clinical Services net receivables.
Income Taxes	Income Taxes The benefit for income taxes and the effective tax rates for the three and nine months ended April 30, 2020 and 2019 is $0 and 0%, respectively. The primary difference between the Company’s effective tax rates and the statutory rates for the three and nine months ended April 30, 2020 and 2019 is due to the change in net operating losses for which a full valuation allowance is maintained. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize its deferred tax assets.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Apr. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of segment revenue and revenue percentage	Three months ended Three months ended Revenue category Third-party payer $ 5,082 52 % $ 5,799 50 % Medicare 1,870 19 2,634 22 Patient self-pay 1,655 17 1,881 16 HMO’s 1,132 12 1,437 12 Total $ 9,739 100 % $ 12,000 100 % Nine months ended Nine months ended Revenue category Third-party payer $ 17,878 51 % $ 20,213 53 % Medicare 8,048 23 7,724 20 Patient self-pay 4,621 13 5,652 15 HMO’s 4,485 13 4,459 12 Total $ 35,032 100 % $ 38,048 100 %
Schedule of product revenue by geographical	Three Months Ended April 30 Nine Months Ended April 30 2020 2019 2020 2019 United States $ 3,458 $ 4,585 $ 11,652 $ 12,571 Europe 1,793 2,297 5,740 6,347 Rest of the world 1,166 1,029 3,323 3,283 Products revenue $ 6,417 $ 7,911 $ 20,715 $ 22,201

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Apr. 30, 2020
Inventory Disclosure [Abstract]
Schedule of inventory current	April 30, July 31, Raw materials $ 907 $ 876 Work in process 2,652 2,566 Finished products 4,459 4,400 $ 8,018 $ 7,842

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	9 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of indefinite-lived intangible assets	Gross Accumulated Amortization Net July 31, 2019 $ 27,238 $ (26,206 ) $ 1,032 Amortization expense — (451 ) (451 ) Foreign currency translation 47 (40 ) 7 April 30, 2020 $ 27,285 $ (26,697 ) $ 588
Schedule of intangible assets	April 30, 2020 July 31, 2019 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (11,010 ) $ 17 $ 11,027 $ (10,996 ) $ 31 Customer relationships 11,791 (11,220 ) 571 11,746 (10,745 ) 1,001 Website and acquired content 1,009 (1,009 ) — 1,008 (1,008 ) — Licensed technology and other 475 (475 ) — 483 (483 ) — Trademarks 2,983 (2,983 ) — 2,974 (2,974 ) — Total $ 27,285 $ (26,697 ) $ 588 $ 27,238 $ (26,206 ) $ 1,032
Schedule of useful lives for acquisitions	Useful life assigned Weighted average Customer relationships 8 -15 years Less than 1 year Other intangibles 10 years Less than 2 years

Loans Payable (Tables)

Loans Payable (Tables)	9 Months Ended
	Apr. 30, 2020
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	July 31, 2020 $ 35 2021 144 2022 152 2023 160 2024 167 Thereafter 3,653 $ 4,311 Less: Current portion (142 ) Unamortized mortgage cost (62 ) $ 4,107

Leases (Tables)

Leases (Tables)	9 Months Ended
	Apr. 30, 2020
Leases Disclosure [Abstract]
Schedule of components lease	Leases Balance Sheet Classification April 30, 2020 Assets Operating Right-of-use assets $ 20,812 Finance Property, plant and equipment, net (a) 459 Total lease assets $ 21,271 Liabilities Current: Operating Current portion of operating lease liabilities $ 4,257 Finance Finance leases short term 225 Non-current: Operating Operating lease liabilities, non-current 17,416 Finance Other liabilities and finance leases long term 223 Total lease liabilities $ 22,121
Schedule of lease cost	Lease cost Three Months Ended April 30, 2020 Nine Ended April 30, 2020 Operating lease cost $ 1,466 $ 4,414 Finance lease cost: Amortization of leased assets 61 177 Interest on lease liabilities 7 29 Total lease cost $ 1,534 $ 4,620
Schedule of lease liability maturity	Maturity of lease liabilities Operating leases Finance leases Total Remainder of fiscal 2020 $ 1,473 $ 84 $ 1,557 2021 4,997 188 5,185 2022 3,786 88 3,874 2023 3,284 88 3,372 2024 3,273 37 3,310 Thereafter 9,606 — 9,606 Total lease payments 26,419 485 26,904 Less: Interest (a) (4,746 ) (37 ) (4,783 ) Present value of lease liabilities $ 21,673 $ 448 $ 22,121
Schedule of lease term and discount rate	Lease term and discount rate Weighted-average remaining lease term (years): Operating leases 6.4 years Finance leases 2.7 years Weighted-average discount rate: Operating leases 4.9 % Finance leases 8.1 %

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Apr. 30, 2020
Payables and Accruals [Abstract]
Schedule of accrued liabilities	April 30, July 31, Payroll, benefits, and commissions $ 4,866 $ 5,123 Professional fees 806 774 Legal 2,333 164 Deferred revenue – CARES Act Advance Payment 2,526 — Other 1,183 2,301 $ 11,714 $ 8,362

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Apr. 30, 2020
Stockholders' Equity Note [Abstract]
Schedule of share-based payment arrangement, cost by plan	Three months ended Nine months ended 2020 2019 2020 2019 Stock options $ 206 $ 289 $ 724 $ 521 Restricted stock 1 2 4 5 $ 207 $ 291 $ 728 $ 526
Schedule of share-based payment arrangement, expensed and capitalized, amount	Three months ended Nine months ended 2020 2019 2020 2019 Selling, general and administrative $ 207 $ 291 $ 728 $ 526 $ 207 $ 291 $ 728 $ 526
Schedule of share-based payment arrangement, option, activity	Options Weighted Weighted Aggregate Outstanding at July 31, 2019 2,351,040 $ 4.53 Awarded 773,032 $ 2.40 Exercised — — $ — Cancelled or expired (485,076 ) $ 3.71 Outstanding at end of period 2,638,996 $ 4.05 3.2 years $ 637 Exercisable at end of period 1,457,162 $ 5.10 1.7 years $ 78
Schedule of nonvested performance-based units activity	Grant Date Total Grant Forfeitures Outstanding Fair Market Value At Grant Date (000s) 7/31/2018 32,000 (4,000 ) 28,000 $ 124 1/3/2019 80,500 (10,500 ) 70,000 $ 196 2/25/2020 98,600 — 98,600 $ 217

Segment reporting (Tables)

Segment reporting (Tables)	9 Months Ended
	Apr. 30, 2020
Segment Reporting [Abstract]
Schedule of segment reporting information, by segment	Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 9,739 $ 6,417 — — $ 16,156 Grant income 747 — — — 747 Total 10,486 6,417 — — 16,903 Operating costs and expenses: Cost of revenues 9,133 3,345 — — 12,478 Research and development 395 580 $ 188 — 1,163 Selling, general and administrative 5,902 2,667 — $ 2,492 11,061 Legal and related expenses 52 — — 1,873 1,925 Total operating costs and expenses 15,482 6,592 188 4,365 26,627 Operating loss (4,996 ) (175 ) (188 ) (4,365 ) (9,724 ) Other income (expense): Interest (7 ) 11 — 83 87 Other 1 4 — 130 135 Foreign exchange loss — (358 ) — — (358 ) Loss before income taxes $ (5,002 ) $ (518 ) $ (188 ) $ (4,152 ) $ (9,860 ) Depreciation and amortization included above $ 373 $ 278 $ — $ 66 $ 717 Share-based compensation included in above: Selling, general and administrative 21 14 — 172 207 Total $ 21 $ 14 $ — $ 172 $ 207 Capital expenditures $ 225 $ 60 $ — $ — $ 285 Clinical Products Therapeutics Other Consolidated Revenues $ 11,751 $ 7,911 — — $ 19,662 Operating costs, expenses and legal settlements, net: Cost of revenues 10,963 3,397 — — 14,360 Research and development 31 527 $ 223 — 781 Selling, general and administrative 5,960 2,923 — $ 2,037 10,920 Legal fee expense 35 16 — 206 257 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses, and legal settlements, net 16,989 (22,062 ) 223 2,243 (2,607 ) Operating income (loss) (5,238 ) 29,973 (223 ) (2,243 ) 22,269 Other income (expense): Interest (18 ) 19 — 257 258 Other 6 — — 64 70 Foreign exchange loss — (332 ) — — (332 ) (Loss) income before income taxes $ (5,250 ) $ 29,660 $ (223 ) $ (1,922 ) $ 22,265 Depreciation and amortization included above $ 440 $ 340 $ — $ 58 $ 838 Share-based compensation included in above: Selling, general and administrative 40 24 — 135 199 Total $ 40 $ 24 $ — $ 135 $ 199 Capital expenditures $ 120 $ 446 $ — $ — $ 566 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 35,032 $ 20,715 — — $ 55,747 Grant income 747 — — — 747 Total 35,779 20,715 — — 56,494 Operating costs and expenses: Cost of revenues 30,351 10,223 — — 40,574 Research and development 1,118 1,599 $ 565 — 3,282 Selling, general and administrative 18,012 7,954 — $ 6,927 32,893 Legal and related expenses 140 1 — 5,540 5,681 Total operating costs and expenses 49,621 19,777 565 12,467 82,430 Operating income (loss) (13,842 ) 938 (565 ) (12,467 ) (25,936 ) Other income (expense): Interest (29 ) 45 — 479 495 Other 20 (1 ) — 315 334 Foreign exchange loss — (88 ) — — (88 ) Income (loss) before income taxes $ (13,851 ) $ 894 $ (565 ) $ (11,673 ) $ (25,195 ) Depreciation and amortization included above $ 1,174 $ 781 $ — $ 196 $ 2,151 Share-based compensation included in above: Selling, general and administrative 88 58 — 582 728 Total $ 88 $ 58 $ — $ 582 $ 728 Capital expenditures $ 514 $ 205 $ — $ — $ 719 Clinical Products Therapeutics Other Consolidated Revenues $ 38,048 $ 22,201 — — $ 60,249 Operating costs, expenses and legal settlements, net: Cost of revenues 32,956 10,391 — — 43,347 Research and development 31 1,645 $ 668 — 2,344 Selling, general and administrative 18,220 8,828 — $ 6,339 33,387 Legal fee expense 109 24 — 2,567 2,700 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses and legal settlements, net 51,316 (8,037 ) 668 8,906 52,853 Operating income (loss) (13,268 ) 30,238 (668 ) (8,906 ) 7,396 Other income (expense): Interest (51 ) 49 — 761 759 Other 17 — — 232 249 Foreign exchange loss (gain) — (530 ) — — (530 ) (Loss) income before income taxes $ (13,302 ) $ 29,757 $ (668 ) $ (7,913 ) $ 7,874 Depreciation and amortization included above. $ 1,217 $ 1,025 $ — $ 130 $ 2,372 Share-based compensation included in above: Selling, general and administrative 118 74 — 553 725 Total $ 118 $ 74 $ — $ 553 $ 725 Capital expenditures $ 883 $ 524 $ — $ 6,147 $ 7,554

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019	Aug. 01, 2019
Basis of Presentation (Details) [Line Items]
Right-of-use assets (in Dollars)					$ 24.4
Right-of-use operating lease liability (in Dollars)					$ 25.1
Deferred rent credit, current (in Dollars)	$ 0.7		$ 0.7
Income tax expense (in Dollars)	$ 0	$ 0	$ 0	$ 0
Income tax effective tax rates	0.00%	0.00%	0.00%	0.00%
Clinical Services [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage			58.00%	63.00%
Clinical Services [Member] | Third Party Payer And Health Maintenance Organizations [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage			12.00%
Clinical Services [Member] | Revenue Benchmark [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage		42.00%	26.00%	42.00%
Third-party payers” and “Health Maintenance Organizations [Member] | Clinical Services [Member] | Revenue Benchmark [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage	22.00%

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Unvested Restricted Stock [Member] | In The Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	40,000		56,000
Out Of The Money Stock Options [Member] | Outstanding Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,201,000	1,640,000	1,805,000	1,541,000

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Third Party Payer And Health Maintenance Organizations [Member] | Minimum [Member]
Revenue Recognition (Details) [Line Items]
Billing Information Filing Deadline Period	60 days
Third Party Payer And Health Maintenance Organizations [Member] | Maximum [Member]
Revenue Recognition (Details) [Line Items]
Billing Information Filing Deadline Period	90 days
Government Payer Medicare [Member]
Revenue Recognition (Details) [Line Items]
Billing Information Filing Deadline Period	60 days
Patient self-pay [Member]
Revenue Recognition (Details) [Line Items]
Billing Period	91 days
Receivable Collection Period	105 days
Product Revenue [Member]
Revenue Recognition (Details) [Line Items]
Income grant (in Dollars)	$ 747
Claim Period For Return Of Goods	30 days
Product Revenue [Member] | Minimum [Member]
Revenue Recognition (Details) [Line Items]
Receivable Collection Period	30 days
Product Revenue [Member] | Maximum [Member]
Revenue Recognition (Details) [Line Items]
Receivable Collection Period	90 days
Clinical Services [Member]
Revenue Recognition (Details) [Line Items]
Concentration Risk, Percentage	58.00%	63.00%
Clinical Services [Member] | Third Party Payer And Health Maintenance Organizations [Member]
Revenue Recognition (Details) [Line Items]
Concentration Risk, Percentage	12.00%

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule Of Segment Revenue And Revenue Percentage - Clinical Services [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Revenue Recognition (Details) - Schedule Of Segment Revenue And Revenue Percentage [Line Items]
Revenue Services Net	$ 9,739	$ 12,000	$ 35,032	$ 38,048
Revenue Services Net Percentage	100.00%	100.00%	100.00%	100.00%
Third-Party Payer [Member]
Revenue Recognition (Details) - Schedule Of Segment Revenue And Revenue Percentage [Line Items]
Revenue Services Net	$ 5,082	$ 5,799	$ 17,878	$ 20,213
Revenue Services Net Percentage	52.00%	50.00%	51.00%	53.00%
Medicare [Member]
Revenue Recognition (Details) - Schedule Of Segment Revenue And Revenue Percentage [Line Items]
Revenue Services Net	$ 1,870	$ 2,634	$ 8,048	$ 7,724
Revenue Services Net Percentage	19.00%	22.00%	23.00%	20.00%
Patient self-pay [Member]
Revenue Recognition (Details) - Schedule Of Segment Revenue And Revenue Percentage [Line Items]
Revenue Services Net	$ 1,655	$ 1,881	$ 4,621	$ 5,652
Revenue Services Net Percentage	17.00%	16.00%	13.00%	15.00%
HMO’s [Member]
Revenue Recognition (Details) - Schedule Of Segment Revenue And Revenue Percentage [Line Items]
Revenue Services Net	$ 1,132	$ 1,437	$ 4,485	$ 4,459
Revenue Services Net Percentage	12.00%	12.00%	13.00%	12.00%

Revenue Recognition (Details)_2

Revenue Recognition (Details) - Schedule of Product Revenue By Geographical - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Revenue Recognition (Details) - Schedule of Product Revenue By Geographical [Line Items]
Products revenue	$ 6,417	$ 7,911	$ 20,715	$ 22,201
United States [Member]
Revenue Recognition (Details) - Schedule of Product Revenue By Geographical [Line Items]
Products revenue	3,458	4,585	11,652	12,571
Europe [Member]
Revenue Recognition (Details) - Schedule of Product Revenue By Geographical [Line Items]
Products revenue	1,793	2,297	5,740	6,347
Rest of the world [Member]
Revenue Recognition (Details) - Schedule of Product Revenue By Geographical [Line Items]
Products revenue	$ 1,166	$ 1,029	$ 3,323	$ 3,283

Supplemental disclosure for s_2

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Interest paid	$ 204	$ 138
Reductions in measurement right of use assets and liabilities	4,300
Tax on capital paid	79	94
Share based employer amount	$ 836	$ 832

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory current - USD ($) $ in Thousands	Apr. 30, 2020	Jul. 31, 2019
Schedule of inventory current [Abstract]
Raw materials	$ 907	$ 876
Work in process	2,652	2,566
Finished products	4,459	4,400
Total inventory	$ 8,018	$ 7,842

Goodwill and intangible asset_2

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2020	Jul. 31, 2019
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Clinical Services [Member]
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452

Goodwill and intangible asset_3

Goodwill and intangible assets (Details) - Schedule of change in the carrying amount of intangible assets - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Schedule of change in the carrying amount of intangible assets [Abstract]
Gross, Beginning Balance	$ 27,238
Accumulated Amortization, Beginning Balance	(26,206)
Net, Beginning Balance	1,032
Amortization expense, Accumulated Amortization	(451)	$ (741)
Amortization expense, Net	(451)	$ (741)
Foreign currency translation, Gross	47
Foreign currency translation, Accumulated Amortization	(40)
Foreign currency translation, Net	7
Gross, Ending Balance	27,285
Accumulated Amortization, Ending Balance	(26,697)
Net, Ending Balance	$ 588

Goodwill and intangible asset_4

Goodwill and intangible assets (Details) - Schedule of Intangible Assets - USD ($) $ in Thousands	Apr. 30, 2020	Jul. 31, 2019
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,285	$ 27,238
Finite-lived intangible assets, Accumulated Amortization	(26,697)	(26,206)
Finite-lived intangible assets, Net	588	1,032
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(11,010)	(10,996)
Finite-lived intangible assets, Net	17	31
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	11,791	11,746
Finite-lived intangible assets, Accumulated Amortization	(11,220)	(10,745)
Finite-lived intangible assets, Net	571	1,001
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	1,009	1,008
Finite-lived intangible assets, Accumulated Amortization	(1,009)	(1,008)
Finite-lived intangible assets, Net
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	475	483
Finite-lived intangible assets, Accumulated Amortization	(475)	(483)
Finite-lived intangible assets, Net
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	2,983	2,974
Finite-lived intangible assets, Accumulated Amortization	(2,983)	(2,974)
Finite-lived intangible assets, Net

Goodwill and intangible asset_5

Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions	9 Months Ended
	Apr. 30, 2020
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Weighted average remaining useful life	Less than 1 year
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	Less than 2 years
Minimum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Useful life assigned	15 years

Loans Payable (Details)

Loans Payable (Details) - USD ($)	Nov. 27, 2018	Nov. 27, 2018	Apr. 30, 2020
Loans Payable (Details) [Line Items]
Debt Instrument, Face Amount	$ 4,500	$ 4,500
Debt Instrument Maturity Period	10 years
Accured interest	5.09%	5.09%
Debt Instrument, Periodic Payment		$ 30,000
Amortization of Debt Issuance Costs		$ 72,000
Debt instruments of mortgage amount			$ 4,300
Cash Collateral for Borrowed Securities			$ 750,000
Operating lease, description			We assumed from the seller an operating lease for a current tenant at the facility which was extended to June 30, 2020.
Foreign exchange rate amount			$ 4,000
Foreign exchange rate amount			$ 400
Bear interest rate			0.00%
Long term debt term			5 years
Fixed interest rate, description			PPP loans have a 1% fixed interest rate and are due from two to five years.
Maturity date, description			The PPP Loan matures on April 17, 2022 (the “Maturity Date”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty.
Accrued interest			$ 0.01
Intention to audit loans in excess			2,000
Mortgage Agreement [Member]
Loans Payable (Details) [Line Items]
Unamortized mortgage cost			62,000
Citibank NA [Member]
Loans Payable (Details) [Line Items]
Cash Collateral for Borrowed Securities			7,000,000
Citibank NA [Member] | Mortgage Agreement [Member]
Loans Payable (Details) [Line Items]
Unamortized mortgage cost			$ 62,000

Loans Payable (Details) - Sched

Loans Payable (Details) - Schedule of Long-term Debt Instruments - Citibank NA [Member] - Mortgage Agreement [Member] $ in Thousands	Apr. 30, 2020USD ($)
Debt Instrument [Line Items]
2020	$ 35
2021	144
2022	152
2023	160
2024	167
Thereafter	3,653
Long term debt – net	4,311
Less: Current portion	(142)
Unamortized mortgage cost	(62)
Total	$ 4,107

Leases (Details)

Leases (Details) $ in Millions	9 Months Ended
	Apr. 30, 2020USD ($)
Leases (Details) [Line Items]
Lease Option Maximum Extension Period	5 years
Finance Lease Right of Use Asset Accumulated Amortization (in Dollars)	$ 0.9
Minimum [Member]
Leases (Details) [Line Items]
Lease Term Of Contract	1 year
Maximum [Member]
Leases (Details) [Line Items]
Lease Term Of Contract	9 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of Components Lease - USD ($) $ in Thousands		Apr. 30, 2020	Jul. 31, 2019
Assets
Operating, Right-of-use assets		$ 20,812
Finance, Property, plant and equipment, net	[1]	459
Total lease assets		21,271
Current:
Operating, Current portion of operating lease liabilities		4,257
Finance, Finance leases short term		225
Non-current:
Operating, Operating lease liabilities, non-current		17,416
Finance, Other liabilities and finance leases long term		223
Total lease liabilities		$ 22,121
[1]	Accumulated amortization of finance lease assets was approximately $0.9 million as of April 30, 2020.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Lease Cost - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2020
Schedule of Lease Cost [Abstract]
Operating lease cost	$ 1,466	$ 4,414
Finance lease cost:
Amortization of leased assets	61	177
Interest on lease liabilities	7	29
Total lease cost	$ 1,534	$ 4,620

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Lease Liability Maturity $ in Thousands	Apr. 30, 2020USD ($)
Schedule of Lease Liability Maturity [Abstract]
Remainder of fiscal 2020, Operating leases	$ 1,473
Remainder of fiscal 2020, Finance leases	84
Remainder of fiscal 2020, Total	1,557
2021, Operating leases	4,997
2021, Finance leases	188
2021, Total	5,185
2022, Operating leases	3,786
2022, Finance leases	88
2022, Total	3,874
2023, Operating leases	3,284
2023, Finance leases	88
2023, Total	3,372
2024, Operating leases4	3,273
2024, Finance leases	37
2024, Total	3,310
Thereafter, Operating leases	9,606
Thereafter, Finance lease
Thereafter, Total	9,606
Total lease payments, Operating leases	26,419
Total lease payments, Finance leases	485
Total lease payments, Total	26,904
Less: Interest, Operating leases	(4,746)	[1]
Less: Interest, Finance leases	(37)	[1]
Less: Interest, Total	(4,783)	[1]
Present value of lease liabilities, Operating leases	21,673
Present value of lease liabilities, Finance leases	448
Present value of lease liabilities, Total	$ 22,121
[1]	Primarily calculated using the Company's incremental borrowing rate.

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of Lease Term and Discount Rate	Apr. 30, 2020
Weighted-average remaining lease term (years):
Weighted-average remaining lease term:Operating leases	6 years 146 days
Weighted-average remaining lease term:Finance leases	2 years 255 days
Weighted-average discount rate:
Weighted-average discount rate:Operating leases	4.90%
Weighted-average discount rate:Finance leases	8.10%

Accrued Liabilities (Details)

Accrued Liabilities (Details) $ in Thousands	9 Months Ended
	Apr. 30, 2020USD ($)
Payables and Accruals [Abstract]
Payment advance	$ 2,526

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of Accrued Liabilities - USD ($) $ in Thousands	Apr. 30, 2020	Jul. 31, 2019
Schedule of Accrued Liabilities [Abstract]
Payroll, benefits, and commissions	$ 4,866	$ 5,123
Professional fees	806	774
Legal	2,333	164
Deferred revenue – CARES Act Advance Payment	2,526
Other	1,183	2,301
Accrued Liabilities	$ 11,714	$ 8,362

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 03, 2019	Sep. 15, 2017	Feb. 25, 2020	Jan. 05, 2018	Apr. 30, 2020	Jul. 31, 2018	Jul. 31, 2019	Sep. 30, 2017	Dec. 31, 2014	Jan. 31, 2011
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share					$ 0.01		$ 0.01
PercentageOfCommissionPayableOnEquityOffering					3.00%
MaximumOfferingPriceUnderSalesAgreement					$ 20,000				$ 20,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount					$ 1,200
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerms					15 months
Restricted Stock [Member]
Stockholders' Equity (Details) [Line Items]
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerms					9 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number					817
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value					$ 3.34
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount					$ 4
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					811
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value					$ 2
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				5,000,000						3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					935,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
AuthorizedCommonStockThatMayBeIssuedAndSoldUnderSalesAgreement								$ 19,150
SecuritiesThatMayBeSoldUnderTheAgreement		$ 150,000
Executive Officer [Member] | Performance Shares [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares					14,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	70,000		98,600			28,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 196		$ 217			$ 124

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of share-based payment arrangement, cost by plan - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Stockholders' Equity (Details) - Schedule of share-based payment arrangement, cost by plan [Line Items]
Share-based compensation expense	$ 207	$ 291	$ 728	$ 526
Stock options [Member]
Stockholders' Equity (Details) - Schedule of share-based payment arrangement, cost by plan [Line Items]
Share-based compensation expense	206	289	724	521
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based payment arrangement, cost by plan [Line Items]
Share-based compensation expense	$ 1	$ 2	$ 4	$ 5

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of share-based payment arrangement, expensed and capitalized, amount - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement	$ 207	$ 291	$ 728	$ 526
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement	$ 207	$ 291	$ 728	$ 526

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of share-based payment arrangement, option, activity $ / shares in Units, $ in Thousands	9 Months Ended
	Apr. 30, 2020USD ($)$ / sharesshares
Schedule of share-based payment arrangement, option, activity [Abstract]
Outstanding at July 31, 2019 | shares	2,351,040
Outstanding, Weighted Average Exercise Price at July 31, 2019 | $ / shares	$ 4.53
Awarded, Options | shares	773,032
Awarded, Weighted Average Exercise Price | $ / shares	$ 2.40
Cancelled or expired, Options | shares	(485,076)
Cancelled or expired, Weighted Average Exercise Price | $ / shares	$ 3.71
Outstanding, Options at end of period | shares	2,638,996
Outstanding, Weighted Average Exercise Price at end of period | $ / shares	$ 4.05
Outstanding, Weighted Average Remaining Contractual Term	3 years 73 days
Outstanding at end of period | $	$ 637
Exercisable, Options at end of period | shares	1,457,162
Exercisable, Weighted Average Exercise Price at end of period | $ / shares	$ 5.10
Exercisable, Weighted Average Remaining Contractual Term	1 year 255 days
Exercisable at end of period | $	$ 78

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Schedule of nonvested performance-based units activity - Executive Officer [Member] - Performance Shares [Member] - USD ($) $ in Thousands	Jan. 03, 2019	Feb. 25, 2020	Jul. 31, 2018
Stockholders' Equity (Details) - Schedule of nonvested performance-based units activity [Line Items]
Total Grant	80,500	98,600	32,000
Forfeitures	(10,500)		(4,000)
Outstanding	70,000	98,600	28,000
Fair Market Value At Grant Date (in Dollars) (in Dollars)	$ 196	$ 217	$ 124

Segment reporting (Details)

Segment reporting (Details)	9 Months Ended
	Apr. 30, 2020
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of Segment Reporting Information, by Segment - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Clinical Services [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	$ 9,739		$ 35,032
Grant income	747		747
Total	10,486		35,779
Cost of revenues	9,133	$ 10,963	30,351	$ 32,956
Research and development	395	31	1,118	31
Selling, general and administrative	5,902	5,960	18,012	18,220
Legal fee expense		35		109
Total operating costs, expenses and legal settlements, net		16,989		51,316
Legal and related expenses	52		140
Total operating costs and expenses	15,482		49,621
Operating income (loss)	(4,996)	(5,238)	(13,842)	(13,268)
Interest	(7)	(18)	(29)	(51)
Other	1	6	20	17
Foreign exchange loss
Income (loss) before income taxes	(5,002)	(5,250)	(13,851)	(13,302)
Depreciation and amortization included above	373	440	1,174	1,217
Selling, general and administrative	21	40	88	118
Total	21	40	88	118
Total	21	40	88	118
Capital expenditures	225	120	514	883
Revenues		11,751		38,048
Products [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	6,417		20,715
Total	6,417		20,715
Cost of revenues	3,345	3,397	10,223	10,391
Research and development	580	527	1,599	1,645
Selling, general and administrative	2,667	2,923	7,954	8,828
Legal fee expense		16		24
Legal settlements, net		(28,925)		(28,925)
Total operating costs, expenses and legal settlements, net		(22,062)		(8,037)
Legal and related expenses			1
Total operating costs and expenses	6,592		19,777
Operating income (loss)	(175)	29,973	938	30,238
Interest	11	19	45	49
Other	4		(1)
Foreign exchange loss	(358)	(332)	(88)	(530)
Income (loss) before income taxes	(518)	29,660	894	29,757
Depreciation and amortization included above	278	340	781	1,025
Selling, general and administrative	14	24	58	74
Total	14	24	58	74
Total	14	24	58	74
Capital expenditures	60	446	205	524
Revenues		7,911		22,201
Other [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products
Grant income
Total
Cost of revenues
Selling, general and administrative	2,492	2,037	6,927	6,339
Legal fee expense		206		2,567
Legal settlements, net
Total operating costs, expenses and legal settlements, net		2,243		8,906
Legal and related expenses	1,873		5,540
Total operating costs and expenses	4,365		12,467
Operating income (loss)	(4,365)	(2,243)	(12,467)	(8,906)
Interest	83	257	479	761
Other	130	64	315	232
Foreign exchange loss
Income (loss) before income taxes	(4,152)	(1,922)	(11,673)	(7,913)
Depreciation and amortization included above	66	58	196	130
Selling, general and administrative	172	135	582	553
Total	172	135	582	553
Total	172	135	582	553
Capital expenditures				6,147
Revenues
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	16,156		55,747
Grant income	747		747
Total	16,903		56,494
Cost of revenues	12,478	14,360	40,574	43,347
Research and development	1,163	781	3,282	2,344
Selling, general and administrative	11,061	10,920	32,893	33,387
Legal fee expense		257		2,700
Legal settlements, net		(28,925)		(28,925)
Total operating costs, expenses and legal settlements, net		(2,607)		52,853
Legal and related expenses	1,925		5,681
Total operating costs and expenses	26,627		82,430
Operating income (loss)	(9,724)	22,269	(25,936)	7,396
Interest	87	258	495	759
Other	135	70	334	249
Foreign exchange loss	(358)	(332)	(88)	(530)
Income (loss) before income taxes	(9,860)	22,265	(25,195)	7,874
Depreciation and amortization included above	717	838	2,151	2,372
Selling, general and administrative	207	199	728	725
Total	207	199	728	725
Total	207	199	728	725
Capital expenditures	285	566	719	7,554
Revenues		19,662		60,249
Therapeutics [Member]
Segment Reporting Information [Line Items]
Grant income
Research and development	188	223	565	668
Total operating costs, expenses and legal settlements, net		223		668
Legal and related expenses
Total operating costs and expenses	188		565
Operating income (loss)	(188)	(223)	(565)	(668)
Other
Income (loss) before income taxes	$ (188)	$ (223)	$ (565)	$ (668)

Contingencies (Details)

Contingencies (Details) - USD ($) $ in Millions	Feb. 02, 2019	Apr. 30, 2020	Feb. 05, 2020	Apr. 16, 2019	Feb. 05, 2019
Commitments and Contingencies Disclosure [Abstract]
Equity Method Investment, Ownership Percentage			80.00%
Settlement agreement		$ 0.8
Settlement amount		$ 0.8
Other Commitment					$ 21
Attorney contingency payments				$ 9.5	$ 19.4
Description of one-time payments	The terms of the agreement include one-time payments totaling $14 million to the Company in exchange for fully paid-up, worldwide licenses to Hologic and Grifols.